Matches in Wikidata for { <http://www.wikidata.org/entity/Q96814485> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- Q96814485 description "artículu científicu espublizáu en xunu de 2020" @default.
- Q96814485 description "scientific article published on 29 June 2020" @default.
- Q96814485 description "wetenschappelijk artikel" @default.
- Q96814485 description "наукова стаття, опублікована 29 червня 2020" @default.
- Q96814485 name "Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis" @default.
- Q96814485 name "Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis" @default.
- Q96814485 type Item @default.
- Q96814485 label "Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis" @default.
- Q96814485 label "Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis" @default.
- Q96814485 prefLabel "Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis" @default.
- Q96814485 prefLabel "Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis" @default.
- Q96814485 P1433 Q96814485-9A37994D-A5CA-4111-8DB3-5BD6EB5453B7 @default.
- Q96814485 P1476 Q96814485-60576B2D-C11A-42D8-9169-F53AA503D77A @default.
- Q96814485 P2093 Q96814485-059ED405-A40B-4A81-9F4D-3103FF05A881 @default.
- Q96814485 P2093 Q96814485-113B3743-566D-43D3-B93F-FB93A6D0C9C3 @default.
- Q96814485 P2093 Q96814485-13631252-2A4A-419A-83F8-BEB63F7B4DB4 @default.
- Q96814485 P2093 Q96814485-17A5AB16-F046-4791-AE5B-84099023A602 @default.
- Q96814485 P2093 Q96814485-1E4BC3CF-88AD-4583-945A-CE7ABCC25104 @default.
- Q96814485 P2093 Q96814485-2D55F56C-9C97-46AC-A0C7-C39C6188AF6D @default.
- Q96814485 P2093 Q96814485-41B8F4D0-BEA2-4BA1-AA60-7E709BC11779 @default.
- Q96814485 P2093 Q96814485-4B60FF86-78EC-45FB-954B-076B2AFDF8D0 @default.
- Q96814485 P2093 Q96814485-5C769128-6161-46A1-94B1-3B761F97B8CF @default.
- Q96814485 P2093 Q96814485-5E73F916-360C-4AC7-89FF-240F019A1915 @default.
- Q96814485 P2093 Q96814485-68B3B2E2-AFCE-42A7-8992-0D8F36381FAE @default.
- Q96814485 P2093 Q96814485-6A33E906-1264-4A40-ACEA-851656DE727C @default.
- Q96814485 P2093 Q96814485-70A2E0BE-01FB-43FF-A3E1-C484B1BE25A2 @default.
- Q96814485 P2093 Q96814485-9F4A0260-7582-47F4-A85B-2633D3579B4F @default.
- Q96814485 P2093 Q96814485-AEB1D5F8-2588-45D2-96BA-DB30289DB9D2 @default.
- Q96814485 P2093 Q96814485-CD632CBE-FD18-4899-AE6F-11681535BAE1 @default.
- Q96814485 P2093 Q96814485-D7A8ED58-6E1A-4C35-A961-E7635805D8DE @default.
- Q96814485 P2093 Q96814485-EF5D3267-4219-4D65-B6EA-C16C601658DB @default.
- Q96814485 P2093 Q96814485-F3FCC559-2EF2-4126-B0FB-115A94112DEE @default.
- Q96814485 P31 Q96814485-B67F96D9-BA14-4913-9AB7-2BCC903F7F0D @default.
- Q96814485 P356 Q96814485-B34A14D3-D5F5-4585-9C1E-B0937014C8E6 @default.
- Q96814485 P50 Q96814485-40F8B8D9-9D65-442D-9D8F-C7006932D8F7 @default.
- Q96814485 P50 Q96814485-70F89816-46DC-4876-BF03-C8068C434FF2 @default.
- Q96814485 P50 Q96814485-A1A4BD48-483F-422E-988F-A2DD0540C819 @default.
- Q96814485 P50 Q96814485-C510E32F-F374-4542-AEE9-EBF3A049CD7E @default.
- Q96814485 P50 Q96814485-EBF95B69-61CC-470E-9FF5-82359C37A9A2 @default.
- Q96814485 P577 Q96814485-659787FA-8C61-4F1A-A712-A54FBD21CA65 @default.
- Q96814485 P698 Q96814485-7C793426-5D70-45A5-B5FB-64A892F6C63C @default.
- Q96814485 P356 1078-0432.CCR-20-0953 @default.
- Q96814485 P698 32601075 @default.
- Q96814485 P1433 Q332253 @default.
- Q96814485 P1476 "Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis" @default.
- Q96814485 P2093 "Alessandro D Santin" @default.
- Q96814485 P2093 "Amanda N Fader" @default.
- Q96814485 P2093 "Angeles Alvarez Secord" @default.
- Q96814485 P2093 "Babak Edraki" @default.
- Q96814485 P2093 "Babak Litkouhi" @default.
- Q96814485 P2093 "Dan-Arin Silasi" @default.
- Q96814485 P2093 "David M O'Malley" @default.
- Q96814485 P2093 "Dirk Pikaart" @default.
- Q96814485 P2093 "Elena Ratner" @default.
- Q96814485 P2093 "Karim ElSahwi" @default.
- Q96814485 P2093 "Laura Havrilesky" @default.
- Q96814485 P2093 "Masoud Azodi" @default.
- Q96814485 P2093 "Natalia Buza" @default.
- Q96814485 P2093 "Osama Abdelghany" @default.
- Q96814485 P2093 "Pei Hui" @default.
- Q96814485 P2093 "Peter E Schwartz" @default.
- Q96814485 P2093 "Setsuko Chambers" @default.
- Q96814485 P2093 "Stefania Bellone" @default.
- Q96814485 P2093 "William Lowery" @default.
- Q96814485 P31 Q13442814 @default.
- Q96814485 P356 "10.1158/1078-0432.CCR-20-0953" @default.
- Q96814485 P50 Q38643301 @default.
- Q96814485 P50 Q87073718 @default.
- Q96814485 P50 Q90852337 @default.
- Q96814485 P50 Q96814479 @default.
- Q96814485 P50 Q96814481 @default.
- Q96814485 P577 "2020-06-29T00:00:00Z" @default.
- Q96814485 P698 "32601075" @default.